<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81712">
  <stage>Registered</stage>
  <submitdate>24/11/2006</submitdate>
  <approvaldate>5/12/2006</approvaldate>
  <actrnumber>ACTRN12606000501549</actrnumber>
  <trial_identification>
    <studytitle>The influence of proline betaine in orange juice on homocysteine concentrations in healthy male Caucasians</studytitle>
    <scientifictitle>A study to compare orange juice versus supplementation with proline betaine on homocysteine concentrations in healthy male Caucasians</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Healthy volunteers</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2 />
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Subjects will receive a single dose of two treatments (a, b) in random order. Treatment (a) is 750 mL orange juice, treatment (b) is proline betaine (0.532g dissolved in 750 mL apple juice). The treatment duration will be one day (24 hours) each week for three consecutive weeks with a wash-out period of 6 days between treatments.</interventions>
    <comparator>Subjects will receive a single dose of treatments (c) in random order.                                                                                                                                                                                                       Treatment (c) is a placebo control of 750 mL apple juice only.                                                                                                                                                                                                  The treatment duration will be one day (24 hours) each week for three consecutive weeks with a wash-out period of 6 days between treatments.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Plasma homocysteine concentrations</outcome>
      <timepoint>At baseline and 20, 40, 60 90, 120, 180, 240, 300, 360 minutes and 24 hours post-treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma glycine betaine and proline betaine concentrations </outcome>
      <timepoint>At baseline and 20, 40, 60 90, 120, 180, 240, 300, 360 minutes and 24 hours post-treatment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Urine glycine betaine and proline betaine concentrations</outcome>
      <timepoint>At baseline and 20, 40, 60 90, 120, 180, 240, 300, 360 and 24 hours post-treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy Caucasian volunteers, with a normal fasting plasma homocysteine concentration.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Vitamin B12 or folate deficiency, chronic or acute illness requiring prescription medication, current or previous history of vascular or renal disease, and smokers.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed envelopes</concealment>
    <sequence>Sequence generated using simple randomisation generated by computer software</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>27/11/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>8</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Canterbury Health Laboratories</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>National Heart Foundation</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Christchurch School of Medicine summer studentship programme</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Christchurch School of Medicine</sponsorname>
      <sponsoraddress />
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>People with high blood levels of homocysteine have an increased risk of heart disease and stroke. A previous study by our group has shown that a molecule called 'proline betaine' increased plasma homocysteine levels in rats. Proline betaine is found in the diet with particularly high levels citrus fruits and alfalfa sprouts. This research will investigate whether drinking orange juice raises homocysteine levels healthy male volunteers and if this is a result of proline betaine content. We hope to learn more about how proline betaine influences homocysteine metabolism and whether it has a role in vascular disease.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Canterbury Health Laboratories</ethicname>
      <ethicaddress />
      <ethicapprovaldate>25/10/2006</ethicapprovaldate>
      <hrec>URA/06/02/002</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Clinical Studies Trust</ethicname>
      <ethicaddress />
      <ethicapprovaldate>25/10/2006</ethicapprovaldate>
      <hrec>URA/06/02/002</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Wendy Atkinson</name>
      <address>Clinical Biochemistry Department
Canterbury Health Laboratories
PO Box 151
Christchurch</address>
      <phone>+64 3 3641594</phone>
      <fax />
      <email>wendy.atkinson@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Wendy Atkinson</name>
      <address>Clinical Biochemistry Department
Canterbury Health Laboratories
PO Box 151
Christchurch</address>
      <phone>+64 3 3641594</phone>
      <fax />
      <email>wendy.atkinson@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>